Date(s) - 29/09/2020
10:00 am - 11:30 am
Innovation in oncology care is rapidly evolving due to the growing availability, and use of, biomarker testing. Biomarker testing can be a valuable component of designing a treatment plan for patients to help positively impact outcomes. However, in routine care, levels of biomarker testing can greatly differ. In fact, the increasing number of biomarker-linked targeted therapies can, at times, complicate optimal adoption of biomarker testing.
How do we solve for this challenge?
Joining an expert panel as they discuss barriers that are limiting testing for solid tumor biomarkers in the United States and the impact of these barriers on decision making for treatment plans now and in the context of the changing healthcare ecosystem. They will also offer solutions to help reduce these testing barriers to realize the benefits of truly personalized medicine.
3 Key Take-Aways
- Examine the current state of biomarker testing adoption in the US—Optimal adoption of biomarker testing is necessary for cancer patients to realize the benefits of biomarker-based targeted therapies, yet biomarker testing rates vary greatly across biomarkers and tumor types.
- Explore barriers to optimal biomarker adoption—As biomarker tests and biomarker-based medicines proliferate, the complexity of the patient journey has increased, and a number of barriers hinder optimal use of testing to guide therapy selection.
- Discover proposed approaches to overcome barriers to realize the benefits of truly personalized medicine—With an ever-growing focus on personalized medicine, changes that address testing barriers and spur a robust uptake of biomarker testing in oncology care can enable a future with better patient outcomes.